Skip to main content
NIH funding notice RFA-CA-18-005

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 - Clinical Trial Not Allowed)

Closed on September 28, 2018.

Posted
November 20, 2017
Close date
September 28, 2018
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $353,619 in first-year total cost, median $353,619.

Most frequent study sections

  1. Special Emphasis Panel[ZCA1 TCRB-J (O1)]1

Most frequent institutions

  1. UNIVERSITY OF NEBRASKA LINCOLN1
Competing awards under RFA-CA-18-005 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2019A Single Conical Tube Device for Precision CAR-T Cells Manufacturing1R33CA235326-01LEI, YUGUOUNIVERSITY OF NEBRASKA LINCOLN, NE$353,619ZCA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-CA-18-005: Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 - Clinical Trial Not Allowed) | ScienceDex | ConductScience